# Stereotactic body radiotherapy for early glottic cancers: Is this “The Way”?

## TL;DR

The paper discusses the use of stereotactic body radiotherapy (SBRT) for early glottic cancer, emphasizing its potential and limitations.

## Contribution

The paper highlights the ideal patient population for SBRT and the need for prospective comparison with standard treatments.

## Key findings

- SBRT is promising for early glottic cancer when used in patients with limited tumor extent and no active smoking.
- Using SBRT in an unselected population may lead to severe laryngeal toxicity.
- Prospective studies comparing SBRT to current treatments are needed.

## Abstract

•Patient with limited tumor extent and no active smoking represent the ideal target population to receive SBRT.•SBRT performed in an unselected population can result in severe laryngeal toxicity.•SBRT for early glottic cancer needs to be prospectively compared to current standard treatment modalities.

Patient with limited tumor extent and no active smoking represent the ideal target population to receive SBRT.

SBRT performed in an unselected population can result in severe laryngeal toxicity.

SBRT for early glottic cancer needs to be prospectively compared to current standard treatment modalities.

In the past decades, several options have been designed in order to preserve vocal function in patients with early glottic cancer, such as transoral laser microsurgery, new surgical strategies such as partial laryngectomy and radiation therapy (RT). With the development of new radiation techniques enabling a more accurate delivery of radiation dose, and the possibility to deliver high dose per fraction while sparing adjacent organs-at-risks (OARs), stereotactic body radiotherapy (SBRT) is being increasingly tested in this disease setting. We aimed to shed light on this appealing strategy, as well as to underline both optimal target population and specific technical considerations.